Resveratrol inhibits rhabdomyosarcoma cell proliferation

European Journal of Cancer Prevention

Volumn 14, Issue 4, 2005, Pages 351-356

  Chow, A W ^a,b   Murillo, G ^c   Yu, C ^b   Van Breemen, R B ^b   Boddie, A W ^a,b   Pezzuto, J M ^d   Das Gupta, T K ^a,b   Mehta, R G ^c  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c IIT RESEARCH INSTITUTE   (United States)

^d PURDUE UNIVERSITY   (United States)

Author keywords

Cell proliferation; Resveratrol; Rhabdomyosarcoma

Indexed keywords

CELECOXIB; PIROXICAM; RESVERATROL;

ARTICLE; CANCER PREVENTION; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG INHIBITION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; WESTERN BLOTTING;

ANTICARCINOGENIC AGENTS; BIOPSY, NEEDLE; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; RHABDOMYOSARCOMA; RISK FACTORS; SENSITIVITY AND SPECIFICITY; STILBENES; TUMOR CELLS, CULTURED;

EID: 23344445969     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008469-200508000-00007     Document Type: Article

References (28)

1. Bhat KPL, Kosmeder JW II, Pezzuto JM (2001). Biological effects of resveratrol. Antioxid Redox Signal 3: 1041-1064.
2. Brakenhielm E, Cao R, Cao Y (2001). Suppression of angiogenesis tumor growth and wound healing by resveratrol. FASEB J 15: 1798-1800.
3. Creasy LL, Creasy MT (1998). Grape chemistry and the significance of resveratrol: an overview. Pharmac Biol 36: 8-13.
4. Delia Ragione F, Cucciolla V, Borreiello A, et al. (1998). Resveratrol arrests the cell division cycle at S/G2 Transition. Biochem Biophys Res Commun 250: 53-58.
5. Elder DJE, Halton DE, Hague A, Paraskeva C (1997). Induction of apoptotic cell death in human colorectal carcinoma cell lines by cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin Cancer Res 3: 1679-1683.
6. Fremont L (2000). Biological effects of resveratrol. Life Sci 66: 663-673.
7. Granados-Soto V (2003). Pleiotropic effects of resveratrol. Drug News Perspect 16: 299-307.
8. Holmes-McNary M, Baldwin Jr AS (2000). Chemopreventive properties of transresveratrol are associated with inhibition of activation of the Iκkinase. Cancer Res 60: 3477-3483.
9. Hsieh TC, Darzynkiewicz Z, Wu JM (1999). Resveratrol increases nitric oxide synthase, induces accumulation of p53 and p21 (WAF1/CIP1), and suppresses cultured bovine pulmonary artery endothelial cell proliferation by perturbing progression through S and G2. Cancer Res 59: 2596-2601.
10. Jang M, Cai L, Udeani GO, et al. (1997). Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220.
11. Joki T, Heese O, Nikas DC, et al. (2000). Expression of cyclooxygenase 2 (COX) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-3981. Cancer Res 60: 4926-4931.
12. Kim YA, Rhee SH, Park KY, et al. (2003). Antiproliferative effect of resveratrol in human prostate carcinoma cells. J Med Food 6: 273-280.
13. Liang YC, Tsai SH, Chen L, Lin-Shiau SY, Lin JK, et al. (2003). resveratrol-induced G2 arrest through the inhibition of CDK7 and p34CDC2 kinases in colon carcinoma HT29 cells. Biochem Pharmacol 65: 1053-1060.
14. Manna SK, Mukhopadhyay A, Aggarwal BB (2000). Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-κB, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 164: 6509-6519.
15. McAllister RM, Melnyk J, Finklestein JZ, et al. (1969). Cultivation in vitro of cells derived from a human rhabdomyosarcoma. Cancer 24: 520-526.
16. Mitchell SH, Zhu W, Young YF (1999). Resveratrol inhibits the expression and function of the androgen receptor in LNCaP cancer cells. Cancer Res 59: 5892-5895.
17. Murillo G, Salti GI, Kosmeder JW 2nd, et al. (2002). Deguelin inhibits the growth of colon cancer cells through the induction of apoptosis and cell cycle arrest. Eur J Cancer 38: 2446-2454.
18. Mutoh M, Takahashi M, Fukuda K, et al. (2000). Suppression of cyclooxygenase-2 promotor-dependent transcriptional activity in colon cancer cells by chemopreventive agents with a resorcin-type structure. Carcinogenesis 21 : 959-963.
19. Siemann EH, Creasy LL (1992). Concentration of the phytoalexin resveratrol in wine. Am J Enol Vitic 43: 49-52.
20. Soleas GJ, Diamandis EP, Goldberg DM (1997). Resveratrol: a molecule whose time as come? And gone? Clin Biochem 30: 91-113.
21. Tessitore L, Davit A, Sarotto I, Caderni G (2000). Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21cip expression. Carcinogenesis 21: 1619-1622.
22. Tsan M, White JE, Maheshwari JG, Bremner TA, Sacco J (2000). Resveratrol induces Fas signaling-independent apoptosis in THP-1 human monocytic leukemia cells. Br J Haematol 109: 405-412.
23. Tsubouchi Y, Mukai S, Kawahito, et al. (2000). Meloxicam inhibits growth of non-small cell lung cancer. Anticancer Res 20: 2867-2872.
24. Vane JR, Bakhle YS, Bolting RM (1998). Cycloxygenase 1 and 2. Annu Rev Pharmacol Toxicol 38: 97-120.
25. Vindelov LL, Christensen IJ, Nissen NI (1983). A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3: 323-327.
26. Wang Q, Li H, Wang XW, et al. (2003). resveratrol promotes differentiation and induces Fas-independent apoptosis of human medulloblastoma cells. Neurosci Lett 351: 83-86.
27. Wexler LH, Andrich MP, Venzon D, et al. (1996). Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 14: 362-372.
28. Wolter F, Akoglu B, Clausnitzer A, et al. (2001). Downregulation of the cyclin D1/Cdk4 complex occurs during resveratrol-induced cell cycle arrest in colon cancer cell lines. J Nutr 131: 2197-2203.